Assessment of Retinal Changes Following Intravitreal Aflibercept in 2 Patients With Von Hippel-Lindau Disease-Related Retinal Capillary Hemangioblastoma

JAMA Ophthalmol. 2022 Dec 1;140(12):1243-1244. doi: 10.1001/jamaophthalmol.2022.4425.

Authors

Eleni K Konstantinou¹, Shilpa Kodati¹, Henry E Wiley¹, Tiarnán D L Keenan¹, Catherine A Cukras¹, Richard H Johnston², Alisa T Thavikulwat¹

Affiliations

¹ National Eye Institute, National Institutes of Health, Bethesda, Maryland.
² Edina Retina Consultants, Edina, Minnesota.

PMID: 36301552
DOI: 10.1001/jamaophthalmol.2022.4425

No abstract available

Plain language summary

This case report of 2 patients describes peripheral Von Hippel-Lindau disease associated with a series of aflibercept injections.

Publication types

Research Support, N.I.H., Intramural

MeSH terms

Hemangioblastoma* / diagnosis
Hemangioblastoma* / drug therapy
Humans
Receptors, Vascular Endothelial Growth Factor / therapeutic use
Retinal Neoplasms* / diagnosis
Retinal Neoplasms* / drug therapy
von Hippel-Lindau Disease* / complications
von Hippel-Lindau Disease* / diagnosis

Substances

aflibercept
Receptors, Vascular Endothelial Growth Factor